title: Multiple protonation states of vesicular acetylcholine transporter detected by binding of [3H]vesamicol.
abstract: Vesicular acetylcholine transporter (VAChT) is inhibited by (-)-vesamicol [(-)-trans-2-(4-phenylpiperidino)cyclohexanol], which binds tightly to an allosteric site. The tertiary alkylamine center in (-)-vesamicol is protonated and positively charged at acidic and neutral pH and unprotonated and uncharged at alkaline pH. Deprotonation of the amine has been taken to explain loss of (-)-vesamicol binding at alkaline pH. However, binding data deviate from a stereotypical bell shape, and more binding occurs than expected at alkaline pH. The current study characterizes the binding of (-)-vesamicol from pH 5 to pH 10 using filter assays, (-)-[3H]vesamicol (hereafter called [3H]vesamicol), and human VAChT expressed in PC12(A123.7) cells. At acidic pH, protons and [3H]vesamicol compete for binding to VAChT. Preexposure or long-term exposure of VAChT to high pH does not affect binding, thus eliminating potential denaturation of VAChT and failure of the filter assay. The dissociation constant for the complex between protonated [3H]vesamicol and VAChT decreases from 12 nM at neutral pH to 2.1 nM at pH 10. The simplest model of VAChT that explains the behavior requires a proton at site 1 to dissociate with pK1 = 6.5 +/- 0.1, a proton at site A to dissociate with pKA = 7.6 +/- 0.2, and a proton at site B to dissociate with pKB = 10.0 +/- 0.1. Deprotonation of the site 1 proton is obligatory for [3H]vesamicol binding. Deprotonation of site A decreases affinity (2.2 +/- 0.5)-fold, and deprotonation of site B increases affinity (18 +/- 4)-fold. Time-dependent dissociation of bound [3H]vesamicol is biphasic, but equilibrium saturation curves are not. The contrasting phasicity suggests that the pathway to and from the [3H]vesamicol binding site exists in open and at least partially closed states. The potential significance of the findings to development of PET and SPECT ligands based on (-)-vesamicol for human diagnostics also is discussed.
authors.affiliation: Department of Chemistry and Biochemistry, Neuroscience Research Institute, University of California, Santa Barbara, California 93106, USA.
authors.forename: Parul
authors.initials: P
authors.lastname: Khare
authors.forename: Aubrey R
authors.initials: AR
authors.lastname: White
authors.forename: Stanley M
authors.initials: SM
authors.lastname: Parsons
mesh_terms: D000495:Allosteric Site; D000818:Animals; D001667:Binding, Competitive; D004795:Enzyme Stability; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007700:Kinetics; D008956:Models, Chemical; D016716:PC12 Cells; D010880:Piperidines / Q000378:metabolism* / Q000494:pharmacology; D011522:Protons; D051381:Rats; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D014316:Tritium; D050494:Vesicular Acetylcholine Transport Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000235:genetics / Q000378:metabolism*
chemical_list: D010880:Piperidines; D011522:Protons; D011994:Recombinant Proteins; C493459:SLC18A3 protein, human; D050494:Vesicular Acetylcholine Transport Proteins; D014316:Tritium; C006189:vesamicol
references.citation: J Neurochem. 1998 Sep;71(3):1118-26
references.pmid: 9721736
references.citation: Neurology. 2005 Jan 25;64(2):208-15
references.pmid: 15668415
references.citation: J Med Chem. 2009 Mar 12;52(5):1358-69
references.pmid: 19203271
references.citation: Biochemistry. 2005 Jun 7;44(22):7955-66
references.pmid: 15924414
references.citation: J Neurochem. 1986 Apr;46(4):1214-8
references.pmid: 3950625
references.citation: J Biol Chem. 1997 Feb 28;272(9):5403-8
references.pmid: 9038139
references.citation: J Cell Biol. 1994 Dec;127(6 Pt 1):1603-16
references.pmid: 7798315
references.citation: Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):416-34
references.pmid: 12002720
references.citation: Neuroreport. 1993 Sep 30;4(12):1311-4
references.pmid: 8260611
references.citation: Eur J Pharmacol. 1996 May 23;304(1-3):185-90
references.pmid: 8813601
references.citation: Protein Sci. 2004 Jul;13(7):1832-40
references.pmid: 15215526
references.citation: Biochemistry. 1988 Jul 12;27(14):5262-7
references.pmid: 2844255
references.citation: Science. 2006 May 5;312(5774):741-4
references.pmid: 16675700
references.citation: Protein Eng. 1994 Mar;7(3):291-9
references.pmid: 8177877
references.citation: Science. 2003 Aug 1;301(5633):616-20
references.pmid: 12893936
references.citation: Neurochem Int. 2000 Feb;36(2):113-7
references.pmid: 10676874
references.citation: Biochemistry. 1998 Sep 22;37(38):13400-10
references.pmid: 9748347
references.citation: Anal Biochem. 1976 May 7;72:248-54
references.pmid: 942051
references.citation: J Biol Chem. 2000 Mar 3;275(9):6175-80
references.pmid: 10692409
references.citation: Exp Neurol. 2003 Nov;184 Suppl 1:S68-79
references.pmid: 14597329
references.citation: FASEB J. 2000 Dec;14(15):2423-34
references.pmid: 11099460
references.citation: Science. 2003 Aug 1;301(5633):610-5
references.pmid: 12893935
references.citation: Methods Enzymol. 2004;385:169-84
references.pmid: 15130739
references.citation: Biochemistry. 2004 Sep 7;43(35):11163-74
references.pmid: 15366926
references.citation: Biochimie. 1982 Oct;64(10):915-21
references.pmid: 6817822
references.citation: Int Rev Neurobiol. 1993;35:279-390
references.pmid: 8463062
references.citation: Annu Rev Microbiol. 2008;62:289-305
references.pmid: 18537473
references.citation: J Biol Chem. 1999 Jan 8;274(2):673-80
references.pmid: 9873001
references.citation: J Biol Chem. 2001 Nov 9;276(45):41580-7
references.pmid: 11551909
references.citation: Mol Membr Biol. 2008 Sep;25(6-7):571-83
references.pmid: 19037818
references.citation: Biochemistry. 1992 Jun 30;31(25):5752-62
references.pmid: 1319200
references.citation: Trends Neurosci. 1995 May;18(5):218-24
references.pmid: 7610492
references.citation: Mol Pharmacol. 1993 Sep;44(3):633-41
references.pmid: 8371715
references.citation: Methods Mol Biol. 2010;637:181-219
references.pmid: 20419436
references.citation: Anal Bioanal Chem. 2004 Mar;378(6):1428-48
references.pmid: 15214406
references.citation: Neurochem Res. 2000 Oct;25(9-10):1385-96
references.pmid: 11059809
references.citation: Nat Struct Biol. 2002 Aug;9(8):597-600
references.pmid: 12118242
references.citation: J Biol Chem. 1996 Nov 1;271(44):27229-32
references.pmid: 8910293
references.citation: Mol Pharmacol. 1983 Mar;23(2):431-6
references.pmid: 6835201
references.citation: Biochem Pharmacol. 1995 Mar 15;49(6):791-7
references.pmid: 7702637
references.citation: J Mol Microbiol Biotechnol. 1999 Nov;1(2):257-79
references.pmid: 10943556
references.citation: J Med Chem. 1989 Jun;32(6):1217-30
references.pmid: 2724295
references.citation: J Nucl Med. 1996 Jul;37(7):1192-7
references.pmid: 8965197
references.citation: Biol Psychiatry. 2001 Feb 1;49(3):211-20
references.pmid: 11230872